Regarding the article entitled “Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis”

Lee et al. [ [1] Lee T. Sawicki G.S. Altenburg J. et al. Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis. J Cyst Fibros. 2022; ([Epub ahead of print]) Abstract Full Text Full Text PDF Scopus (5) Google Scholar ] compared participants of ELX/TEZ/IVA clinical trials aged ≥12 years against 2012-2017 controls in the US CF Foundation Patient Registry. An annual ppFEV1 trend of +0.39 (95% CI -0.06 to +0.89) for ELX/TEZ/IVA treated participants contrasted with -1.92 (95% CI -2.16 to -1.69) for controls. They concluded that ELX/TEZ/IVA is the first CF therapy that halts FEV1 decline over a 2-year follow-up period, which included phases of lockdown/shielding due to the Covid-19 pandemic. The use of non-contemporaneous controls was suggested to have limited impact on the finding because a sensitivity analysis showed consistent results for 2012-2014 and 2015-2017 controls, and impact from Covid-19 lockdown/shielding on FEV1 trend was unknown.